China raises levies to 125% on US as Trump trade war escalates - In his first public remarks on Trump's tariffs, President Xi ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere ...

AstraZeneca saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition.

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss ...

pharmaphorum speaks with Steven Davis of AstraZeneca on how the first year of its first direct-to-patient program - ARIMIDEX Direct has been. A year ago, AstraZeneca announced its first direct-to ...

EU Approval for the Expanded Use of AZN’s Key Cancer Drugs AstraZeneca announced that the EC has approved the expanded use of Imfinzi in combination with chemotherapy for treating adults with ...

He started down this path as a student assistant at Cincinnati. After graduating in 2021, Davis followed Bearcats defensive ...